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Helix3 Inc., Morrisville, North Carolina, USA
Despite regulatory directives requiring the reduction of
animal use in safety testing, recent modiﬁcations
to genotoxicity testing guidelines now propose the use of
two in vivo genotoxicity assays as a follow-up to an in vitro
positive (International Conference on Harmonization
Consensus Draft Guidance S2[R1] released March, 2008).
To address both goals, the in vivo comet and micronucleus
(MN) assays can be successfully combined into one
informative study. Combining these two assays with such
differences in sensitivity, endpoints measured and the type
of data generated signiﬁcantly improves upon the current
standard capabilities for detecting genotoxicity without
requiring additional animals. But to take full advantage of
the beneﬁts of incorporating the comet assay in safety
testing, these same differences must be recognized and
considered. Developed from over 15 years experience using
the in vivo comet and MN assays in genotoxicity testing of
chemicals and pharmaceuticals, this paper presents
guidelines for the appropriate experimental design, dose
selection and data interpretation for combined in vivo
comet/MN assay studies. To illustrate the approach, data
from combined assay studies are presented and discussed.
Introduction
Since the European Commission Cosmetic Products Directive in
1976, there has been a signiﬁcant increase in efforts to reduce
the use of animals in safety testing. Meanwhile, to improve the
safety and protection of humans and the environment, the
Registration, Evaluation and Authorization of Chemicals law
entered into force in June, 2007 and the recent modiﬁcation of
the International Conference on Harmonization (ICH) Guidance
on Genotoxicity Testing and Data Interpretation for Pharma-
ceuticals Intended for Human Use S2(R1) now proposes
additional in vivo target organ testing of chemicals as
a follow-up to positive in vitro ﬁndings. In response to the
requirements of these conﬂicting legislative directives, proposals
to combine the in vivo comet assay with the in vivo micronucleus
(MN) assay and/or to integrate the two assays into repeat-dose
toxicity studies are currently under consideration.
As a supplement to the standard test battery for genotoxicity,
the in vivo comet assay is used to screen potential drug
candidates early in development or it is used as a Tier II or
WeightofEvidencestudytoassesstheresultsofinvitroorinvivo
genotoxicitytests.Duetoitsﬂexibility,theinvivocometassaycan
be combined with or incorporated into most standard testing
batteries to provide supplemental target organ data without the
additional expenditure of time and resources required by an
independent study. To ensure that the appropriate study design is
used and an accurate interpretation of the comet data is achieved
fromsuchcombinedstudies,the incorporationofthe comet assay
intostandardgenotoxicitytestsand/ortoxicologystudiesrequires
the recognition of the signiﬁcant differences between the comet
assayandtheMNassay.BasedontheOrganizationforEconomic
Co-operationandDevelopment(OECD)guidelinesfortheinvivo
MN assay (OECD 474), the proposed ICH S2(R1) guidelines
recommend the use of the limit dose (e.g. 2000 mg/kg) or
themaximumtolerateddose(MTD)asthehighdoseinallinvivo
genotoxicity tests including the comet assay. It also states that
concurrent positive control treatments may be excluded once
a laboratory has ‘established competence in the use of the assay’.
Buttheseandsimilarrecommendationsshouldbeadjustedforthe
cometassaytotakefulladvantage ofthe increasedsensitivityand
ﬂexibility it provides. This paper addresses three of the primary
issuesthatarecriticaltothesuccessfulintegrationofthecombined
comet/MN assay and provides recommendations for ensuring the
optimization of each:
  Experimental design,
  Dose selection/cytotoxicity and
  Data analysis and interpretation.
To demonstrate the effectiveness of the protocol/recommen-
dations proposed here, data from several studies are presented
and discussed focusing on the unique aspects of the comet
assay. All studies were blind studies conducted in accordance
with the US Food and Drug Administration (FDA) (21 CFR
Part 58) and the OECD Principles of Good Laboratory Practice
(as revised in 1997), ENV/MC/CHEM (98) 17 and all sub-
sequent consensus documents. Proprietary test article informa-
tion and data are not disclosed.
Materials and methods
Although no deﬁnitive guidelines exist for the comet assay, the test
methodology is in accordance with recommendations by Hartmann et al. and
Burlinson et al. (1,2).
Test animals
Non-fasted virus antibody-free male or female Sprague Dawley rats or CD-1
mice 8–9 weeks of age with a mean body weight (BW) variation of    10% at
the start of dosing were used for each study. Uniquely identiﬁed animals were
single housed in polysulphone cages with absorbent bedding and are maintained
at temperatures of 18–23C with a relative humidity of 40–60% and an air
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12 h of light and 12 h of dark and animals were provided Purina Certiﬁed Rodent
Chow 5002 (Purina Mills, Raleigh, NC) and water ad libitum. All animal
procedures were in compliance with the National Research Council Guide for the
Care and Use of Laboratory Animals (1996) and the US Animal welfare Act
Regulations (9 CFR 1–4). All the protocols and procedures were reviewed and
approved by the Helix3 Institutional Animal Care and Use Committee.
Controls
The concentrations of positive control compounds such as mitomycin C and
cyclophosphamide (CP) that induce MNs in the bone marrow and peripheral
blood can also induce cytotoxicity in any of the multiple tissues that can be
tested in the comet assay. Since cytotoxicity can have confounding effects on
the comet assay by increasing and/or decreasing DNA migration (1,3,4), the
individual compound concentrations and/or the longer exposures that reliably
induce MNs may not be optimal for use with the comet assay. Therefore,
recommendations for combining the two assays in vivo have included (i) the
use of separate positive control dose groups for the two separate assays with at
least four to six animals in each; (ii) the use of one positive control dose group
for comet and the use of positive control slides from independent studies for the
MN positive control or (iii) the exclusion of concurrent positive controls for
one or both endpoints. Either option compromises the beneﬁts of the combined
study either by adding more animals or by removing the ability to make
concurrent control comparisons. It is of critical importance to note here that not
only are concurrent controls necessary for adequate evaluation of comet assay
data but also concurrent control data for each tissue sampled must be included
as different tissues in the same animal can react differently to exposures
depending on the pharmacokinetics of a test compound.
Our protocol for integrating the two assays into one study with either rats or
mice avoids using any additional animals or resources by providing from the
same group of animals concurrent positive control data for both endpoints and
in every tissue sampled. In our protocol, the positive control group of animals
received a combination of intraperitoneal (i.p.) injections of CP (CAS no. 6055-
19-2; Sigma, St Louis, MO) with an oral (p.o.) administration of ethyl
methanesulphonate (EMS; CAS no. 62-50-0; Sigma, St. Louis, MO) to induce
in the same group of animals a positive MN response in the bone marrow and/
or the peripheral blood as well as a positive comet response in any tissue
sampled. In the typical rodent MN assay study, a single administration (either
by i.p. injection or oral gavage) of CP 24 h prior to harvest is sufﬁcient for
inducing a positive genotoxic response in the bone marrow while an
administration of CP 48 h prior to harvest induces a positive response in the
peripheral blood. Therefore, for studies in which the induction of MNs in both
the bone marrow and the peripheral blood were to be evaluated, the positive
control group received an i.p. injection of CP at 25 mg/kg BW once daily on
two consecutive days and 24 h apart with the sample harvest at 24 h after the
ﬁnal injection. To avoid interfering with the comet assay in the gastrointestinal
tract, i.p. injection was the route of administration for the CP. For studies
evaluating just one sample type for MNs, animals received a single i.p.
injection of CP either 24 (bone marrow) or 48 h (peripheral blood) prior to
sampling. In the typical rodent comet assay study, a single oral administration
of EMS 3–4 h prior to harvest is sufﬁcient for inducing a positive genotoxic
response in any tissue sampled. A single administration of EMS at 200 mg/kg is
typically sufﬁcient for inducing a positive comet assay response in the liver.
But in our experience and as reported by Hartmann et al. (6), a 300 mg/kg
concentration of EMS provides a more consistent positive response across
a wider range of tissues when tissues other than just the liver (e.g. gastrointes-
tinal or urinary tract) are evaluated (data not shown). Twenty (20) hours after
the ﬁnal CP dose administration and 4 h prior to sampling, the same group of
animals that were injected with CP also received a single oral administration
of EMS at 200 or 300 mg/kg BW. Both the CP and the EMS were prepared
fresh in dH2O immediately prior to dosing and all doses were administered in
a volume of 10 ml/kg.
Experimental design
Dose selection and sample times. The greatest strength of the comet assay is its
ability to detect in target organs initial and/or acute DNA damage in the
absence of any clinical signs of stress or toxicity and after exposures as short as
1–4 h depending on the pharmacokinetics of the test compound. But these
initial lesions can be repaired or lead to cell death (cytotoxicity) and/or
mutations, thus decreasing the amount of damage detectable by the comet assay
at later time points when clastogenic effects are most likely to be detected. This
may require comet sample collection at a time point (e.g. 4 h after the second
dose administration) that is different from the time point at which the MN
samples should be collected (e.g. 24 h after 14 daily dose administrations).
In addition, it is important to note that the doses used in standard toxicology
tests or dose range ﬁnders are typically based on single daily dose
administrations (e.g. 2000 mg/kg) approximately 24 h apart. However in the
comet assay, animals can receive 2 dose administrations (e.g. 2   2000 mg/kg
or 4000 mg/kg) within 24 h of sampling. This can result in higher cytotoxicity
in the comet assay than what was detected at the same dose in a standard
test.
Therefore, information about the kinetics and cytotoxicity of a test
compound should be obtained prior to or concurrently with the combined
and/or integrated comet/MN assay. This would enable one to ensure that the
dosing and sampling times for the two assays are appropriate for achieving
adequate but non-cytotoxic exposure of the target samples. Although the
inclusion of the MTD, the dose sufﬁcient to elicit a biological response (e.g.
toxicity) in the target tissue or the test system is preferred by regulatory
agencies in genotoxicity testing, it has been acknowledged by the European
Medicines Agency (EMEA) that the use of such a dose could prove to be
unattainable since dose-limiting toxicity can occur in a tissue other than the
target tissue of interest (5). In such cases, the minimum dose at which
cytotoxicity occurs in any tissue may be considered the MTD. However, as
recommended by Hartmann et al. (6) and the EMEA, toxicokinetic and/or
autoradiographic data should be used to provide evidence of test compound
bioavailability and target tissue exposure at the time of sampling.
Cytotoxicity. Although histopathology is often referred to as the ‘Gold
Standard’ measurement of in vivo cytotoxicity (2), the EMEA and
pathologists recognize the insensitivity of this methodology and therefore
emphasize that the absence of histological ﬁndings does not exclude toxicity
(7–9). While the earliest histological evidence of necrosis may not manifest
for several hours to days, tissue-speciﬁc enzymes and proteins that are
released from necrotic cells can be detected in the blood as early as 1–2 h after
cell death (8,9). Therefore, detecting tissue-speciﬁc and irreversible cell injury
and death using plasma enzyme levels (8,9) or the low molecular weight
(LMW) DNA diffusion assay (1,2) may be more relevant to the comet assay.
To determine the possible effects of cytotoxicity on the comet assay results,
we recommend concurrently conducting the LMW DNA diffusion assay. To
ensure that the dose range tested includes at least two to three non-cytotoxic
doses, an LMW DNA diffusion assay dose range ﬁnder using the same dosing
schedule as the comet assay and including at least two animals per dose group
may be conducted. Alternatively, additional dose groups may be included in
the comet assay study to ensure that at least two to three non-cytotoxic doses
are evaluated.
For the studies presented in this paper, dosing and the sample times for the
animals exposed to the test article (proprietary data, not shown) were based on
pharmacokinetic/toxicity data provided by the sponsor and/or on the results of
a dose range ﬁnder conducted by Helix3 with the LMW DNA diffusion assay.
Although dose administration schedules varied depending on the study, all the
studies included at least two dose administrations within 24 h of sampling with
one dose 20 h prior to sampling and one more 4 h prior to sampling. Every
study included the LMW DNA diffusion assay and histopathology evaluation
as concurrent measurements of cytotoxicity.
Comet sample collection
Animals were anaesthetized by CO2 before they were euthanized by
exsanguination 4 h after the ﬁnal dose administration. During exsanguination,
peripheral blood comet assay samples were collected from each animal and
processed directly to slides. Immediately after exsanguination, at least three
additional tissue samples per animal were collected. In the studies presented,
the additional comet tissue samples analysed included the liver, bone marrow,
duodenum and urinary bladder. To determine germ cell genotoxicity and/or
genotoxicity related to the reproductive tract (10), multiple gender-speciﬁc
tissues (e.g. prostate and testis) and hormone-regulating tissues from the
neuroendocrine pathway (e.g. hypothalamus, thyroid, pineal and/or pituitary
gland) were also analysed.
MN sample collection
During exsanguination, peripheral blood MN samples were also collected from
each animal. Peripheral blood samples were smeared onto at least two slides per
animal. After exsanguination, bone marrow samples were collected on slides by
ﬂushing at least one femur per animal with foetal bovine serum.
Histopathology sample collection
Additional portions of the tissue samples collected for the comet assay from the
test compound and vehicle control animals were also retained in ﬁxative
(SafeFix II, Fisher Scientiﬁc, Suwanee, GA) for histopathology.
Comet assay
The standard procedure for preparing and processing comet assay slides as
described by Hartmann et al. (1) was used. However, since background
migration levels can vary depending on the tissue type and procedures may
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cross-links) of genotoxicity (6), the sample and slide processing conditions
used (e.g. electrophoresis time) for each tissue and study were adjusted as
necessary to ensure that the methodology was appropriate for providing
migration levels in the vehicle control samples sufﬁcient for the sensitive
detection of differences. Collected tissue samples were ﬂushed with mincing
solution (Mg
þþ- and Ca
þþ-free Hanks balanced salt solution, 10% v/v
dimethyl sulfoxide (DMSO) and 20 mM ethylenediaminetetraacetic acid,
disodium salt (Na2EDTA), pH 7.4–7.7) and maintained cold and moist with
mincing solution until they were minced to produce a cell suspension. For each
comet slide prepared, an aliquot of minced cell suspension or peripheral blood
was mixed with 0.5% low-melting point agarose, layered onto microscope
slides pre-coated with 1% normal melting point agarose and covered with an
additional layer of 0.5% low-melting point agarose. To ensure adequate gel
adhesion and to minimize intra- and inter-study migration variability, slides
were prepared in an environment with a constant relative humidity of  60%.
After slides were prepared, they were placed in cold working lysing solution
(2.5 M NaCl, 100 mM Na2EDTA, 10 mM Tris, pH 10, with 10% v/v DMSO
and 1% v/v Triton X-100) and lysed at 4C. After at least 1 h in lysis, two
replicate slides per sample were rinsed with 0.4 M Tris buffer (pH 7.5) before
treating with alkaline electrophoresis buffer (300 mM NaOH, 1 mM Na2EDTA,
pH . 13) for 20 min. Electrophoresis times are optimized for each study/tissue.
However, for direct comparisons, all the tissues presented in this paper were
electrophoresed for 40 min at 0.7 V/cm, 300 mA and 4C. After
electrophoresis, slides were neutralized with 0.4 M Tris (pH 7.5), dipped in
100% ethanol and allowed to air-dry. Air-dried slides were stained with
SYBR Gold stain (Molecular Probes, Eugene, OR) and 100 cells (50 cells per
replicate slide) were scored per sample using the Komet GLP Image Analysis
System (Andor Technology, Belfast, UK). All slides were scored without
knowledge of their identity. DNA migration was determined as the olive tail
moment (OTM; measured as the distance between the centre of gravity of the
DNA distribution in the tail and the centre of gravity of the DNA distribution in
the head multiplied by the fraction of DNA in the tail), the density of migrated
DNA (% Tail) and the distance that DNA migrated (TL, tail length in microns
measured from the estimated trailing edge of the head). However, since the
OTM and the % Tail are the measurements most laboratories with image
analysis systems use for dose group comparisons, these are the measurements
of focus in this paper.
LMW DNA diffusion assay
Depending on the degree and stage of apoptosis/necrosis of the cells at the time
the comet slides are prepared, cytotoxicity-related DNA fragmentation can
contribute to increased DNA migration levels in the total cell population that
can be misinterpreted as a genotoxic effect (i.e. ‘false positive’) or it can
contribute to decreasing DNA migration levels (i.e. ‘false negative’) due to the
loss of detectable DNA following overnight lysis and electrophoresis
(3,4,11,12). Due to this potentially confounding effect of cytotoxicity on the
in vivo comet assay, a concurrent detection of tissue-speciﬁc necrosis and/or
apoptosis is essential to the accurate interpretation of DNA migration data (6).
But as stressed by pathologists in Robbins Pathologic Basis of Disease (1999),
cytotoxic pharmaceuticals can induce in tissues considerable apoptosis before it
becomes apparent in histological sections. And due to the time lag between
stress and the morphological manifestations of necrosis, evidence of these
changes may not be detectable by means other than electron microscopy for
12 h to days after irreversible injury has been induced even when that injury
was induced within 20–60 min of exposure (8). Complicating matters further,
dye exclusion viability assays (e.g. Trypan blue exclusion) are inadequate for
use with in vivo comet due to the mincing of tissues and the disruption of cell
membranes caused by this process.
The LMW DNA diffusion assay (also known as the diffusion assay or the
neutral diffusion assay) is a sensitive and single-cell detection of apoptosis/
necrosis that can easily be conducted concurrently with the comet assay by
preparing an extra and identical replicate comet slide that will be removed from
lysis after 1 h and ﬁxed without electrophoresis. After only 1 h of lysis and in
the absence of electrophoresis, the nuclear DNA of live cells (even those with
extensive DNA damage) will appear mostly condensed under microscopic
evaluation. But cells with extensive DNA degradation caused by endonuclease
activity during apoptosis or necrosis can quickly exhibit a progressively diffuse
pattern as increasing amounts of LMW DNA diffuse through the agarose
matrix and away from the nucleus. There are overlaps and variations in cellular
events that can occur in different tissues and cells. However, the general trend
in LMW DNA diffusion in single cells and the corresponding histopathological
ﬁndings in whole tissues are represented in Figure 1.
If cells are processed to comet slides while they are in the initial or early
stages of apoptosis/necrosis, the LMW DNA fragments that are larger and
therefore closest to the nucleus immediately after lysis can contribute to an
increase in DNA migration levels following electrophoresis. But if cells are
Fig. 1. The progression of cytotoxicity. Before cellular swelling and/or condensation are visible by gross or microscopic examination of a tissue, the earliest
detectable measurements of cell death can include an increase in the percentage of individual cells with LMW DNA diffusion and/or evidence of depleted glycogen
(e.g. decreased cytoplasmic pallor) in tissue sections. With the lysis of the necrotic cell membranes, more advanced LMW DNA diffusion, increased plasma enzyme
levels and/or cytoplasmic eosinophilia (i.e. inﬂammation) in the tissue may be detected. However, the stage at which tissue necrosis/apoptosis and post-necrotic
effects (e.g. compensatory hyperplasia/hypertrophy) can be detected by histopathology is too advanced to be detected by the LMW DNA diffusion assay as
complete digestion and clearance of the individual dead cells has occurred.
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stages of apoptosis/necrosis, DNA migration levels may be decreased as the
signiﬁcantly smaller LMW DNA fragments and even all evidence of a cell’s
existence are lost to phagocytosis/extracellular digestion and/or advanced
diffusion of the fragments during lysis and electrophoresis. Depending on the
dose response curve of the test compound and the range of the doses tested, this
decrease in DNA migration at cytotoxic doses (i.e. doses at which
histopathological evidence of necrosis is present) as has been experienced by
Hartmann et al. (6) and Helix3 can be misinterpreted as an absence of
a genotoxic effect (i.e. false negative) when genotoxicity can occur at the lower
non-cytotoxic doses as illustrated in Figures 3 and 4.
It is important to note here that while the infamous ‘hedgehog’-shaped
comets following electrophoresis can be most likely be attributed to
genotoxicity and not cytotoxicity (1,12–14), assessment of diffusion immedi-
ately after  1 h of lysis and in the absence of electrophoresis is more likely to
capture evidence of cytotoxicity due to the speed and nature of the LMW DNA
degradation associated with cell death (12,13). However, unlike viability assays
such as those that measure ATP levels, membrane permeability or metabolic
competency, the LMW DNA diffusion assay does not provide a deﬁnitive
measurement by which ‘acceptable limits’ (e.g. .70%) may be established.
And unlike histopathology evaluation that detects whole tissue necrosis, the
LMW DNA diffusion assay also does not provide a deﬁnitive marker for cell
death by which the exclusion of certain data may be justiﬁed. Nor does it
distinguish between apoptosis and necrosis. But rather, it provides single-cell
data about the pre-processed condition of the nuclear DNA with which detected
migration patterns in the comet assay may be interpreted and/or qualiﬁed.
An example of how the LMW DNA diffusion data were used in a study to
help interpret the comet assay results is presented in Figures 2 and 3. In the
presented study, the non-toxic test compound was initially tested with the MTD
as the high dose and 0.5  and 0.25  the MTD as the mid and low doses,
respectively (Figure 2). With a statistically signiﬁcant (P , 0.05) increase in
DNA migration present only at the low dose, the conclusion may have been an
equivocal or negative classiﬁcation of genotoxicity. However, a signiﬁcant
increase in LMW DNA diffusion was also detected at the low dose. This
combined with the concordant and dose-related decreases in both migration and
diffusion at the mid and high doses appeared to indicate that cytotoxicity and
the loss of DNA fragments were confounding factors in the determination of
genotoxicity at the doses tested. To determine the genotoxicity of the
compound in the absence of cytotoxicity, a second experiment was conducted
with 0.125  the MTD as the high dose and 0.0625  and 0.0313  as the mid
and low doses, respectively. At these doses, signiﬁcant increases in DNA
migration but not in LMW DNA diffusion were detected at 0.125  and
0.0625  the MTD (Figure 3). Therefore, based on a complete set of the data
providing a clear hormetic (\ shaped) dose response curve for the test
compound, the compound was classiﬁed as positive for genotoxicity with the
lowest observable adverse effect level (LOAEL) at 0.0625  the MTD. This
study data demonstrate that both genotoxicity and cytotoxicity may be detected
at doses well below an MTD that was based on clinical signs and/or
histopathology (Figure 4).
Although a positive control group was included in the experiments
presented in Figures 2 and 3, these data are not included as it is not relevant
to the discussion on the LMW DNA diffusion assay. EMS is an established
genotoxin that can also induce cytotoxicity in some tissues depending on that
tissue’s sensitivity. And since the purpose of the positive control is just to
verify that the study conditions were sufﬁcient for detecting a positive response,
the inﬂuence of cytotoxicity on the magnitude of the positive control response
is not relevant to the interpretation of comet assay data for test compound
exposures.
To assess the percentage of cells with LMW DNA diffusion (% LMW
DNA) the methodology described by Vasquez (3) was used. Brieﬂy, one
replicate comet assay slide from each sample was removed from lysis after 1 h,
neutralized with 0.4 M Tris buffer (pH 7.5), dipped in alcohol and air-dried.
Air-dried slides were stained with SYBR Gold (Molecular Probes) and 100
cells per slide were scored visually for the percentage of diffused versus
condensed cells. All slides were scored without knowledge of their identity. It
is important to note here that the use of low-signal/high background (e.g.
ethidium bromide) or quickly fading (e.g. SYBR Green) stains and/or a slow
deliberate scoring technique can mask or introduce diffusion during scoring,
making scores seem inconsistent. In our experience, using the slower-fading,
high-signal/background SYBR Gold stain with an immediate ﬁrst assessment
scoring technique of coded slides are the best methods for ensuring consistent
and accurate diffusion scores.
MN assay
MN slides were air-dried before they were ﬁxed in alcohol, air-dried and
stained with acridine orange. After staining, 2000 immature erythrocytes
(polychromatic erythrocytes, PCEs) per sample (1000 cells per replicate slide)
were scored for the incidence of MNs (% MN-PCEs). To assess for a decrease
in the ratio of PCEs to total erythrocytes indicative of toxicity or bone marrow
suppression, 1000 erythrocytes per sample (500 cells per replicate slide) were
scored for the percentage of PCEs (% PCEs). All slides were scored without
knowledge of their identity.
Fig. 2. Dose-related decreases in DNA migration and LMW DNA diffusion in
response to cytotoxicity of pharmaceutical tested up to the MTD. For viewing
on same graph scale with LMW data, OTM values were multiplied by 3. Star
indicates statistically signiﬁcant increase at P , 0.05.
Fig. 3. Hormetic (\ shaped) dose response curve of pharmaceutical tested in
the comet assay. For viewing the same graph scale with LMW data, OTM
values were multiplied by 3. Star indicates statistically signiﬁcant increase at
P , 0.05.
Fig. 4. Possible dose response curves in the comet assay. While the common
assumption is that genotoxicity is most likely to be detected at doses
immediately below the MTD (- - -), the genotoxic effect as well as the
confounding effects of tissue cytotoxicity (—) and even very steep dose
response curves (....) can be detected in the comet assay at doses signiﬁcantly
lower than the MTD.
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To evaluate for the presence of cytotoxicity using histopathology, samples of
the comet tissues were embedded in parafﬁn. In studies where a compound was
positive or equivocal for genotoxicity in the comet assay, the tissues in which
the effect was detected were prepared to slides, stained with haematoxylin and
eosin and evaluated by a veterinary pathologist. Typical morphological changes
considered indicative of cell injury and/or death include but are not limited to
cellular swelling/shrinking, inﬂammation, atypical cytoplasm, increased
eosinophilia, pyknosis, karyolysis, karyorrhexis and/or compensatory hyper-
plasia/hypertrophy (8,9). However, as there may be less obvious markers for
cell death, the pathologist microscopically evaluated for and reported the
presence of any morphological changes compared to normal tissue.
Statistical analysis
Statistical analysis with Analyse-It Software (Leeds, UK) and using individual
animal data was conducted on the extent of DNA migration as determined by
the OTM and the % Tail, on the % LMW DNA and on the % MN-PCEs. The
Shapiro–Wilk test with a conﬁdence level of 95% was conducted on the
concurrent vehicle control data to determine the normality of the baseline level
distribution. Since test compound exposures can induce either increases or
decreases in DNA migration and/or LMW DNA diffusion and studies were
conducted blindly without advance provision of mechanistic data, one-tailed
tests were used and directional P-values (þ for increases;   for decreases) for
signiﬁcant differences are reported to assist with determining the shape of the
dose response curve and interpreting the results. If the data were normally
distributed in the concurrent vehicle control (supplementary Figure I, available
at Mutagenesis Online), a parametric independent sample t-test with a 95%
conﬁdence level and the Welch’s approximation for unequal variances (if
applicable) was used to compare dose group means to the mean of the
concurrent vehicle control. A parametric linear regression test with a 95%
conﬁdence level was used to determine the presence of a dose response. If the
data were not normally distributed in the concurrent vehicle control
(supplementary Figure II, available at Mutagenesis Online), a non-parametric
Mann–Whitney test with a 95% conﬁdence level was used to compare dose
group medians and a non-parametric Kendall correlation (also known as
Jonckheere–Terpstra) test was used to determine the presence of a dose
response. Alternatively (and for a direct comparison to the non-parametric
statistical analysis), the OTM data that were not normally distributed were
normalized by log (natural) transforming the individual cell data after
0.001 was added to each data point to circumvent the potential problem of
taking the log of 0. After the natural log transformation (log[n]), the same
parametric tests listed above were used to analyse the log transformed data as
recommended by Wiklund and Agurell (15) (Table VIII). A one-way analysis
of variance (ANOVA) with a Dunnett’s post hoc test was also compared to the
parametric methods described above (data not shown) with no change in the
results between the different statistical analyses.
Although a mean difference in effect of  2-fold and/or a mean difference of
 5% in % Tail DNA has been suggested as possible criteria for a positive
response when comparing dose groups to the concurrent vehicle control, these
criteria do not address or account for the distribution of the data, inter-animal
variability [standard deviation (SD)] or the equality of variances between the
compared dose groups and may thus be misleading when attempting to make
conclusions about genotoxicity. Therefore, it is more appropriate and objective
to use statistical analysis with the appropriate adjustments for distribution and
variability and predetermined criteria (e.g. 95% conﬁdence levels) for
determining the signiﬁcance of the genotoxic response.
Determination of a positive response
Use of historical control data. Signiﬁcant differences between the MN assay
and the comet assay in the way a response is expressed (probability of a change
versus magnitude of the change) and the sensitivity with which the response is
measured (quantal versus continuous) dictate that the data from these two assays
should be evaluated differently. Most genotoxicity endpoints including the MN
assay use binomial classiﬁcation to measure the probability of a response by
determining the percentage of damaged cells in a population. However, quantal
or discrete data such as these are limited to a ﬁnite range of integers and are
therefore very insensitive or imprecise due to its susceptibility to counting error
and/or inter-animal variability (16–18). For this reason, historical control data are
often used with in vivo MN studies to increase the sample size and thereby the
sensitivity of dose group comparisons and/or to provide a range of values by
which concurrent control data can be validated (19).
Unlike the MN assay, the comet assay scored by image analysis uses an
inﬁnite range of possible values to measure the magnitude of the change in
response by determining the amount of damage or migration induced in
individual cells. This continuous scale method provides more information and
uses the data more effectively than the quantal method which takes ﬁve times as
much data to achieve the same results (20). This sensitivity differential is
particularly evident in studies using four to six animals per dose group where
the MN assay would require scoring at least 20 000 cells per sample to detect
a 2- to 3-fold increase (17) while the comet assay can detect the same 2- to
3-fold increase in damage with up to 80% power by scoring only 100–150 cells
per sample (21). With this kind of inherent sensitivity in the comet assay, it is
clear that including historical control data to increase the sample size and
sensitivity is unnecessary.
Recent modiﬁcations to the ICH guidelines recommend using historical
control comet data to determine the range of vehicle control values within
which small but signiﬁcant increases in migration are not biologically relevant
or by which a threshold effect may be determined. But the almost inﬁnite
variety of cell/tissue types, test systems, vehicle controls and experimental
conditions with which the comet assay can be used makes it difﬁcult or
impossible to generate sufﬁcient and comparable historical control data for
every applicable tissue and study design. Even if such a database is developed,
the result will be a continuously expanding range of migration levels as even
signiﬁcant differences between the effects of vehicles such as dH2O and methyl
cellulose on different tissues can be detected (data not shown), thus making
comparisons to the range of vehicle control migrations far less relevant than
comparisons to the concurrent controls. Therefore, comparisons between
experiments should be limited to comparing the general dose response
(e.g. signiﬁcant and dose-dependent increase in migration) or single change in
effect (e.g. signiﬁcant increase in migration only at cytotoxic dose) in relation
to the concurrent controls for the respective experiment.
Historical control comet data should only be used to demonstrate adequate
proﬁciency with the techniques and to justify the methodologies (e.g.
electrophoresis conditions) used for processing and analysing a particular
sample type under the required experimental conditions.
Dose response curve. When determining the dose response or change in effect,
it is critical to note that due to the sensitivity of the comet assay, the detected
low-dose effect may follow a non-linear (e.g. J or U shaped) or even hormetic
(\ shaped) response curve where the signiﬁcant (and perhaps more biologically
relevant) genotoxic effect may be ,2-fold greater than the vehicle control and
present at doses signiﬁcantly lower than the MTD (Figures 3 and 4). This is
particularly evident in studies in which confounding factors such as toxicity,
tissue-speciﬁc cytotoxicity, compound bioavailability, cellular repair and
division/turnover and/or cell cycle inhibition can inﬂuence DNA migration
patterns (3,4). Although the probability of a hormetic response in a toxicology
study has been debated by many, this phenomenon in genotoxicity has been
recognized by the members of the International Workgroup on Genotoxicity
Testing in vivo comet group (2) as it has been shown to occur in some in vivo
MN studies (22). Further, a 2005 review by Calabrese and Blain (23) of
toxicological study data containing  5600 dose response relationships across
.900 agents from a diverse spectrum of compounds concluded that hormetic
dose response relationships occur across numerous animal models and species
and across a broad range of susceptibilities to toxic agents.
It was also noted in the Calabrese and Blain (23) review that the
quantitative features of the hormetic response revealed that the vast majority
(80%) of cases displayed a maximum stimulatory response ,2-fold
(approximately only 30–60%) greater than the control in endpoints ranging
from mutagenesis to immune or metabolic responses to carcinogenesis.
Meanwhile, the width of the stimulatory response in nearly 90% of the cases
was ,100-fold in dose range immediately below the toxicological no
observed adverse effect level (NOAEL). This effect has also been frequently
evident in some tissues evaluated with the comet assay where the maximum
response to a powerful carcinogen such as EMS can be  2-fold greater
than the minimum response to the vehicle control. Meanwhile, a statistically
signiﬁcant (P , 0.05) and dose-dependent increase in response can
reside well within the range between the vehicle and positive control and
at doses well below the MTD and even well below the NOAEL. While
one cannot help but question the biological relevance of such a small
(,2-fold) magnitude of change, it is important to note that one motivation
for including the comet assay in safety testing was to take advantage of
its increased sensitivity for detecting low levels of damage that might
otherwise go undetected by the standard assays from which the  2-fold
response criteria were originally developed. Further, the Calabrese and
Blain (23) review concluded that not only were the majority of
stimulatory responses typically of both modest magnitude and width but
also these dose response characteristics are biologically signiﬁcant since they
occur independent of biological model, endpoint, chemical class and physical
agent.
Data interpretation. In our view, it is best for the determination of a positive
response in the comet assay to limit comparisons of dose groups to the
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made based on the detected response relative to the range between the
concurrently detected minimum response (e.g. vehicle or sham control) and
the maximum response detected (e.g. positive control or high dose if the
response is greater than the response detected in the positive control) under the
experimental conditions of the study as recommended by Murrel et al. (24).
Although statistical analysis is recommended for the determination of the
signiﬁcance of a response, it is important to note that it should only be used to
aid in the interpretation of the data. But as a basic guide for genotoxicity
classiﬁcations using the comet assay and in agreement with Hartmann et al. (1),
we recommend the following:
A test compound may be positive if both of the following criteria are met:
(a) A signiﬁcant (P , 0.05) increase (indicative of strand breaks) or decrease
(indicative of cross-links) in DNA migration in any tissue evaluated is
detected in at least one dose group and
(b) a signiﬁcant (P , 0.05) dose-dependent increase or decrease in DNA
migration in the same tissue is detected.
A test compound may be classiﬁed as equivocal for genotoxicity if either (a)
or (b) is met, but not both. If an increase in cytotoxicity as measured by LMW
DNA diffusion (P , 0.05), plasma enzyme levels and/or histopathological
ﬁndings is detected in the same tissue and at the same dose concentrations at
which DNA migration is signiﬁcantly increased or decreased, cytotoxicity
should be considered a confounding factor in the determination of genotoxicity.
In such cases, a repeat test with the same and/or lower doses may be necessary
to verify the presence of genotoxicity in the absence of cytotoxicity. If neither
(a) nor (b) is met, the test compound may be classiﬁed as negative for
genotoxicity. To conﬁrm the results of an experiment and/or the biological
relevance of the response, the reproducibility of the effect should be tested in an
independent experiment.
The ﬁnal interpretation of the comet assay results and any conclusions made
should
(1) consider the appropriateness of the dose selection/sample time,
(2) account for the possibility that a non-linear or non-monotonic dose–
response relationship may exist,
(3) describe any confounding factors (e.g. cytotoxicity and bioavailability)
and how they may have inﬂuenced the migration data and
(4) classify genotoxicity and/or biological relevance based on the
reproducibility of a signiﬁcant response in independent experiments
rather than on the absolute magnitude (e.g. x-fold) of the response.
To that effect, it is important for the appropriate and unbiased interpretation
of the comet assay dose response to always analyse and report data from every
dose group in an experiment regardless of any other effects (e.g. cytotoxicity)
that may be present at a particular dose. While many argue that different
biological mechanisms such as cytotoxicity play a role at higher doses
compared to mechanisms such as genotoxicity at lower doses, this does not
imply that the overall dose–response relationship of the mechanisms operate
independently of one another. To best understand the dose response of such
biological mechanisms and their potential inﬂuence on DNA migration, all the
data should be presented and addressed for objective review and evaluation.
Preemptive exclusion of data provides an incomplete view of the dose response
curve and potentially biases the interpretation of results.
Results
The combined in vivo MN and comet assay study proposed in
this paper has been in consistent use at Helix3 for over 5 years.
To illustrate the effective combination of the assays, a sample
of the historical control data from multiple tissues in mice
(Table I) and rat studies (Tables II and III) with similar dosing
schedules is provided. For studies presented in Tables I and II,
both the bone marrow and peripheral blood were evaluated for
the presence of MNs. From the same animals, somatic cells
from multiple tissues were also evaluated for genotoxicity with
the comet assay. In these studies, the positive control animals
were dosed by i.p. injection with CP once daily for two
consecutive days and 24 h apart. Twenty (20) hours after the
second dose administration and 4 h before sampling, the same
group of animals received an oral administration of EMS. For
studies presented in Table III, the bone marrow was the only
sample evaluated for the presence of MNs. But from the same
animals, germ cell genotoxicity and genotoxicity related to the
reproductive tract was evaluated with the comet assay in
multiple gender-speciﬁc tissues and in hormone-regulating
tissues from the neuroendocrine pathway (10). In these studies,
the positive control animals were dosed once with CP 24 h
before sampling and once with EMS 4 h before sampling. For
all the studies, animals exposed to the test article (proprietary
data not shown) or the vehicle were dosed once daily for 3–4
consecutive days and 24 h apart with an additional adminis-
tration 20 h after the last dose and 4 h prior to sampling. The
vehicle control animals received administrations of either
dH2O or 0.5% methyl cellulose and each dose group consisted
of ﬁve to six animals.
To provide additional support and examples for the data
interpretation and criteria proposed in this paper, the data and
results from two acute studies evaluating the dose response in
DNA damage induced in rats following oral administrations of
a dose range of EMS are also presented and discussed.
Study 1
To compare the sensitivity of the comet and MN assays for
detecting DNA damage in comparable tissues of animals
Table I. Combined comet/MN assay in male CD-1 mice
Study ID Dose Bone marrow MN Peripheral blood MN
% PCEs
(mean   SD)
% MN-PCEs
(mean   SD)
% PCEs
(mean   SD)
% MN-PCEs
(mean   SD)
A Vehicle 51.9   10.42 0.08   0.094 5.5   1.21 0.04   0.058
Positive
a 33.2   10.44 0.63   0.170 3.9   0.88 0.23   0.133
B Vehicle 37.7   3.71 0.05   0.045 5.8   1.99 0.07   0.141
Positive
a 25.9   11.47 0.80   0.230 2.7   1.05 0.18   0.097
Study ID Dose Liver comet Peripheral blood comet Duodenum comet
% Tail DNA
(mean   SD)
OTM
(mean   SD)
% LMW
(mean   SD)
% Tail DNA
(mean   SD)
OTM
(mean   SD)
% LMW
(mean   SD)
% Tail DNA
(mean   SD)
OTM
(mean   SD)
% LMW
(mean   SD)
A Vehicle 6.8   0.49 0.8   0.26 11.8   15.60 6.5   0.97 0.5   0.07 0.2   0.41 15.9   2.80 3.5   1.04 14.3   8.59
Positive
a 28.9   9.26 8.0   3.46 27.3   20.27 32.2   9.63 7.6   3.66 13.0   14.30 41.6   13.81 12.3   5.31 18.0   8.39
B Vehicle 11.3   1.37 2.3   0.54 13.2   6.68 10.4   1.12 1.3   0.09 1.3   1.97 24.0   5.17 7.4   2.41 15.3   7.09
Positive
a 22.4   3.75 6.4   1.60 33.8   17.10 20.7   2.74 5.5   1.34 9.0   3.85 31.4   3.35 10.0   1.60 20.8   9.85
aTwo i.p. administrations of 25 mg/kg CP 20 h apart þ 300 mg/kg EMS p.o. and 4 h pre-necropsy.
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or 100 mg/kg BW was orally administered to animals once
daily on two consecutive days and 24 h apart based on the 48-
and 24-h sample time requirements for the peripheral blood and
bone marrow MN assay. Twenty (20) hours after the second
dose administration and 4 h prior to sampling, the same group
of animals received an additional dose administration. This
third and ﬁnal dose administration was included to be
Table III. Combined comet/bone marrow MN in male Sprague Dawley rats
Study ID Dose Bone marrow MN Hypothalamus comet Thyroid comet
% PCEs
(mean   SD)
% MN-PCEs
(mean   SD)
% Tail DNA
(mean   SD)
OTM
(mean   SD)
% LMW
(mean   SD)
% Tail DNA
(mean   SD)
OTM
(mean   SD)
% LMW
(mean   SD)
E Vehicle 58.4   7.98 0.08   0.052 23.7   5.92 6.9   3.26 11.8   11.55 11.0   2.06 2.3   0.57 5.8   2.71
Positive
a 48.7   11.58 1.19   0.501 45.4   8.87 15.3   3.87 21.5   8.83 31.7   7.18 9.9   3.31 9.3   6.31
F Vehicle 43.8   6.12 0.13   0.076 20.1   3.79 4.8   1.35 6.7   4.76 10.5   2.03 1.9   0.85 2.8   2.23
Positive
a 44.4   6.71 1.47   0.408 43.8   5.77 13.3   1.81 13.2   5.91 24.7   3.44 6.4   0.87 12.9   10.61
Study ID Dose Liver comet Duodenum comet Pituitary comet
% Tail DNA
(mean   SD)
OTM
(mean   SD)
% LMW
(mean   SD)
% Tail DNA
(mean   SD)
OTM
(mean   SD)
% LMW
(mean   SD)
% Tail DNA
(mean   SD)
OTM
(mean   SD)
% LMW
(mean   SD)
E Vehicle 5.0   1.16 0.6   0.17 4.0   2.53 27.1   6.93 9.4   3.14 18.7   3.01 12.1   2.14 2.2   0.58 3.2   2.04
Positive
a 24.1   6.85 6.1   2.16 17.8   8.33 43.3   9.70 14.4   4.21 21.2   9.45 29.2   7.83 8.4   3.02 7.2   4.17
Prostate comet Testis comet Pineal comet
F Vehicle 11.4   1.93 1.9   0.71 7.2   3.82 9.3   1.59 1.5   0.44 13.5   6.38 11.8   1.55 2   0.48 5.2   2.14
Positive
a 23.5   1.69 5.4   0.79 9.0   3.46 16.9   2.06 3.3   0.35 20.5   11.55 30.5   7.77 7.8   2.63 19.7   13.87
aOne i.p. administration of 25 mg/kg CP 24 h pre-necropsy þ 300 mg/kg EMS p.o. and 4 h pre-necropsy.
Table II. Combined comet/MN assay in male Sprague Dawley rats
Study ID Dose Bone marrow MN Peripheral blood MN
% PCEs
(mean   SD)
% MN-PCEs
(mean   SD)
% PCEs
(mean   SD)
% MN-PCEs
(mean   SD)
C Vehicle 39.1   12.60 0.07   0.052 7.1   0.87 0.01   0.020
Positive
a 28.2   8.04 2.58   0.392 2.8   0.12 0.15   0.126
D Vehicle 37.6   18.39 0.10   0.040 6.7   1.82 0.00   0.000
Positive
b 15.4   3.40 1.90   0.450 2.2   1.31 0.28   0.328
Study ID Dose Liver comet Peripheral blood comet Duodenum comet
% Tail DNA
(mean   SD)
OTM
(mean   SD)
% LMW
(mean   SD)
% Tail DNA
(mean   SD)
OTM
(mean   SD)
% LMW
(mean   SD)
% Tail DNA
(mean   SD)
OTM
(mean   SD)
% LMW
(mean   SD)
C Vehicle 8.3   1.41 1.50   0.64 2.20   1.17 6.5   0.45 0.70   0.19 0.70   0.52 22.5   2.43 6.8   1.56 10.8   7.47
Positive
a 28.5   1.76 9.00   0.85 6.30   3.83 32.5   3.36 8.80   1.45 17.70   4.50 46.8   1.66 16.7   1.33 20.5   5.36
Bone marrow comet
D Vehicle 7.8   1.69 1.2   0.44 4.8   3.06 6.2   0.85 0.50   0.09 1.20   2.40 15.6   2.11 4.5   0.66 4.8   1.47
Positive
b 17.5   2.25 4.3   1.00 10.0   5.93 19.0   3.71 4.00   0.95 12.20   5.34 26.6   2.55 8.1   0.87 15.2   7.08
aTwo i.p. administrations of 25 mg/kg CP 20 h apart þ 300 mg/kg EMS p.o. and 4 h pre-necropsy.
bTwo i.p. administrations of 25 mg/kg CP 20 h apart þ 200 mg/kg EMS p.o. and 4 h pre-necropsy.
Table IV. Comet assay evaluation of bone marrow in rats exposed to three administrations of EMS
Dose (mg/kg) TL (mean   SD) % Tail OTM % LMW DNA
Mean   SD P-value
a Mean   SD P-value
a Mean   SD P-value
a
Positive 50.4   3.88 26.6   2.55 , þ0.0001* 8.1   0.87 , þ0.0001* 15.2   7.08 þ0.008*
Vehicle 39.1   2.93 15.6   2.11 — 4.5   0.66 — 4.8   1.47 —
25 44.5   4.06 19.1   3.56 þ0.0323* 5.2   1.41 0.1538 11.5   4.04 þ0.004*
50 49.7   4.55 21.6   2.18 þ0.0004* 6.4   0.99 þ0.001* 19.7   8.12 þ0.003*
100 50.7   5.51 28.7   4.15 , þ0.0001* 8.9   1.63 , þ0.0001* 12.2   3.82 þ0.0007*
One-tailed trend test P-value , þ0.0001* , þ0.0001* þ0.0375*
Data based on 100 cells scored per animal; six animals per dose group.
aOne-tailed pairwise comparison of dose group to the concurrent vehicle control.
*Statistically signiﬁcant increase (þ) or decrease ( )a tP , 0.05.
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cometassay.However,sinceitwasadministeredonly4hpriorto
sampling, it did not contribute to or impact the exposure for the
MNassay.Therefore,theresponsedetectedintheMNassaywas
only based on two daily dose administrations while the response
detected in the comet assay was based on three dose
administrations. But for consistency in reporting, all the data
tables for this study refer to the total number (3) of dose
Table V. MN assay evaluation of bone marrow in rats exposed to three administrations of EMS
Dose (mg/kg) % PCEs (mean   SD) % MN-PCEs (mean   SD) P-value
a
Positive 15.4   3.40 1.9   0.45 ,0.001*
Vehicle 37.6   18.39 0.1   0.04 —
25 29.4   15.16 0.0   0.04 0.998
50 28.2   7.60 0.1   0.10 0.226
100 25.9   6.65 0.2   0.09 0.093
One-tailed trend test P-value 0.026*
Data based on 1000 cells per animal for % PCEs; 2000 PCEs per animal for % MN-PCEs; six animals per dose group.
aOne-tailed pairwise comparison of dose group to the concurrent vehicle control.
*Statistically signiﬁcant increase at P , 0.05.
Table VI. Comet assay evaluation of peripheral blood in rats exposed to three administrations of EMS
Dose (mg/kg) TL (mean   SD) % Tail OTM % LMW DNA
Mean   SD P-value
a Mean   SD P-value
a Mean   SD P-value
a
Positive 31.6   3.49 19.0   3.71 þ0.0001* 4.0   0.95 þ0.0002* 12.2   5.34 þ0.0011*
Vehicle 7.2   1.98 6.2   0.85 — 0.5   0.09 — 1.2   2.40 —
25 19.8   1.88 11.3   1.66 , þ0.0001* 1.5   0.29 þ0.0001* 2.5   2.07 0.1969
50 28.1   1.33 15.0   1.62 , þ0.0001* 2.7   0.38 , þ0.0001* 9.2   2.93 þ0.0022*
100 34.9   2.93 20.8   4.03 þ0.0001* 4.5   1.26 þ0.0003* 11.7   6.31 þ0.0022*
One-tailed trend test P-value , þ0.0001* , þ0.0001* , þ0.001*
Data based on 100 cells scored per animal; six animals per dose group.
aOne-tailed pairwise comparison of dose group to the concurrent vehicle control.
*Statistically signiﬁcant increase (þ) or decrease ( )a tP , 0.05.
Table VII. MN assay evaluation of peripheral blood in rats exposed to three administrations of EMS
Dose (mg/kg) % PCEs
(mean   SD)
% MN-PCEs
(mean   SD
P-value
a
Positive 2.2   1.31 0.28   0.328 0.001*
Vehicle 6.7   1.82 0.00   0.000 —
25 5.0   0.58 0.02   0.026 0.197
50 6.0   2.63 0.03   0.041 0.090
100 4.6   1.58 0.00   0.000 0.531
One-tailed trend test P-value 0.385
Data based on 1000 cells per animal for % PCEs; 2000 PCEs per animal for % MN-PCEs; six animals per dose group.
aOne-tailed pairwise comparison of dose group to the concurrent vehicle control.
*Statistically signiﬁcant increase at P , 0.05.
Table VIII. Comet assay evaluation of liver in rats exposed to three administrations of EMS
Dose (mg/kg) TL (mean   SD) % Tail OTM OTM log(n) % LMW DNA
Mean   SD P-value
a Mean   SD P-value
a Mean   SD P-value
a Mean   SD P-value
a
Positive 39.9   4.96 17.5   2.25 , þ0.0001* 4.3   1.00 þ0.0010* 1.3   0.25 , þ0.0001* 10.0   5.93 þ0.0436*
Vehicle 21.5   4.94 7.8   1.69 — 1.2   0.44 —  0.8   0.39 — 4.8   3.06 —
25 30.7   3.47 11.7   1.33 þ0.0006* 1.9   0.30 þ0.0043* 0.2   0.18 , þ0.0001* 3.2   1.94 0.1432
50 39.4   5.10 16.3   1.95 , þ0.0001* 3.6   0.78 þ0.0011* 1.1   0.22 , þ0.0001* 7.7   3.56 0.0851
100 49.1   2.95 25.2   1.26 , þ0.0001* 7.0   0.60 þ0.0011* 1.8   0.05 , þ0.0001* 12.7   4.80 þ0.0036*
One-tailed trend test P-value , þ0.0001* , þ0.0001* , þ0.0001* þ0.0001*
Data based on 100 cells scored per animal; six animals per dose group.
aOne-tailed pairwise comparison of dose group to the concurrent vehicle control.
*Statistically signiﬁcant increase (þ) or decrease ( )a tP , 0.05.
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194administrations (Tables IV–IX). The dose concentrations were
selected based on rat toxicity data and bone marrow MN data
indicating a NOAEL at 20 mg/kg/day in the rat after 4 weeks of
dosingandsampling24hafterthelastdose(E.Glocke,L.Mu ¨ller,
unpublished data). The positive control dose group received
a single oral administration of 200 mg/kg EMS 4 h prior to
sampling. From each animal, bone marrow and peripheral blood
were collected and analysed for both the comet and MN assays.
Theliverwasalsocollectedfromeachanimalandanalysedforthe
cometassay.Anadditionalportionofthesamesectionoftheliver
analysed withthecometassaywasalso evaluatedby a veterinary
pathologist for evidence of cytotoxicity.
Bone marrow. The summary of the bone marrow comet
analysis is presented in Table IV and the summary of MN
assay analysis is presented in Table V. The bone marrow OTM,
% Tail and % LMW DNA data for the concurrent vehicle
control were normally distributed (P 5 0.165, 0.421 and 0.804,
respectively). Therefore, parametric tests were used for the
statistical analysis of these parameters. The percentage of
micronucleated PCEs (% MN-PCEs) for the concurrent vehicle
control was normally distributed (P 5 0.87). Therefore,
parametric tests were used for statistical analysis of the MN
data. After two daily administrations of EMS followed by
a third administration 4 h prior to sampling (three total
administrations within 48 h), the comet assay mean   SD
minimum (Min) to maximum (Max) dose response range for
the OTM was 4.5   0.66 to 8.1   0.87. For the % Tail, the Min
to Max dose response range was 15.6   2.11 to 26.6   2.55%.
Based on the OTM, a statistically signiﬁcant and dose-
dependent (P , 0.0001) but ,2-fold increase in DNA
migration was detected in the bone marrow at 50 and 100
mg/kg. Based on the % Tail, a statistically signiﬁcant and dose-
dependent (P , 0.0001) but ,2-fold increase in DNA
migration was detected in the bone marrow at every dose
concentration tested. Based on the % LMW DNA diffusion,
a statistically signiﬁcant and dose-dependent (P , 0.0001)
increase in cytotoxicity was also detected at every dose
concentration tested. A statistically signiﬁcant (P , 0.0001)
increase in DNA migration and in cytotoxicity was detected in
the bone marrow of the positive control group animals.
A signiﬁcant increase neither in micronucleated PCEs nor in
bone marrow suppression was detected by the MN assay at any
dose concentration tested. A signiﬁcant (P , 0.0001) and .10-
fold increase in micronucleated PCEs was detected in the bone
marrow of the positive control group animals.
Peripheral blood. The summary of the peripheral blood comet
assay analysis is presented in Table VI and the summary of the
MN assay analysis is presented in Table VII. The blood OTM
and % Tail data for the concurrent vehicle control were
normally distributed (P 5 0.315 and 0.171, respectively).
Therefore, parametric tests were used for the statistical analysis
of these parameters. The % LMW DNA and % MN-PCE data
were not normally distributed (P 5 0). Therefore, non-
parametric tests were used for the statistical analysis of these
parameters. After three total administrations of EMS within
48 h, the comet assay mean   SD Min to Max dose response
range for the OTM was 0.5   0.09 to 4.0   0.95. For the %
Tail, the Min to Max dose response range was 6.2   0.85 to
20.8   4.03%. Based on the OTM and the % Tail, a statistically
signiﬁcant and dose-dependent (P , 0.0001) increase in DNA
migration was detected in the blood at every dose concentration
tested. Based on the % LMW DNA diffusion, a statistically
signiﬁcant and dose-dependent (P , 0.0001) increase in
cytotoxicity was detected at 50 and 100 mg/kg. A statistically
signiﬁcant (P , 0.0001) increase in DNA migration and in
cytotoxicity was detected in the peripheral blood of the positive
control group animals.
A signiﬁcant increase neither in micronucleated PCEs nor in
bone marrow suppression was detected at any dose concentra-
tion tested. A signiﬁcant (P 5 0.001) and .10-fold increase in
micronucleated PCEs was detected in the bone marrow of the
positive control group animals.
Liver. The summary of the liver comet assay analysis is
presented in Table VIII. The liver OTM data were not normally
distributed (P 5 0.028). Therefore, non-parametric tests were
used for the statistical analysis of this parameter. For
comparison of the different statistical approaches, the liver
OTM data were also log transformed and analysed as described
in the Statistical analysis of this paper. The liver % Tail and %
LMW DNA data for the concurrent vehicle control samples
were normally distributed (P 5 0.145 and 0.846, respectively).
Therefore, parametric tests were used for the statistical analysis
of these parameters. After three total administrations of EMS
within 48 h, the mean   SD Min to Max dose response range
for the OTM was 1.2   0.44 to 7.0   0.60. For the % Tail, the
Min to Max dose response range was 7.8   1.69 to 25.2  
1.26%. Based on both the OTM and the % Tail, a statistically
signiﬁcant and dose-dependent (P , 0.0001) increase in DNA
migration was detected in the liver at every dose concentration
tested with a ,2-fold increase at 25 mg/kg. This response was
unaltered when the OTM data were log transformed and/or
when an alternate method of analysis (e.g. ANOVA with
Dunnett’s test) was conducted. Based on the % LMW DNA
diffusion, a statistically signiﬁcant increase in cytotoxicity was
only detected at 100 mg/kg. A statistically signiﬁcant (P ,
0.0001) increase in DNA migration and in cytotoxicity was
detected in the liver of the positive control group animals.
Table IX. Clinical and microscopic evidence of liver toxicity in rats exposed to three administrations of EMS
Dose (mg/kg) BW gain (g) (mean   SD) Decreased pallor
a (mean   SD) % LMW DNA (mean   SD)
Positive 9.6   7.75** 1.5   0.55** 10.0   5.93**
Vehicle 23.7   5.59 0.0   0.00 4.8   3.06
25 15.7   8.04 0.0   0.00 3.2   1.94
50  2.5   14.33** 0.8   0.75** 7.7   3.56
100  15.5   7.09** 2.0   0.00** 12.7   4.80**
One-tailed trend P-value ,0.0001** ,0.0001** ,0.0001**
aCompared to cytoplasm of normal hepatocytes; severity score based on 1 5 minimal; 2 5 mild.
**Statistically signiﬁcant at P , 0.05.
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toxicity in Study 1, clinical observations and the BWs for each
animal were recorded prior to each dose administration. The
BW gain of each animal was determined by subtracting the
BW at the start of dosing from the BW immediately prior to the
ﬁnal dose administration. Cytotoxicity in the liver was
determined by histopathological evaluation and the LMW
DNA diffusion assay. The summary of weight gain, histopa-
thology and the % LMW DNA diffusion is presented in
Table IX. After three total administrations of EMS within 48 h,
the mean   SD BW gain of the vehicle control animals was
23.7   5.59 with a signiﬁcant (P , 0.0001) and dose-related
decrease in BW gain at doses  50 mg/kg including the positive
control. Histopathological evaluation of the liver samples from
the same animals indicated treatment-induced decreases in
glycogen as determined by decreased cytoplasmic pallor at
doses  50 mg/kg including the positive control (Figure 5).
Based on the statistical analysis conducted on the severity
scores (1 5 minimal; 2 5 mild; 3 5 moderate; 4 5 moderately
severe) for the individual animals, this dose-related effect was
statistically signiﬁcant at P , 0.0001. No pathology of
inﬂammation, gross necrosis and/or apoptosis was detected.
However, since one of the earliest detectable events in both cell
injury and death is the depletion of intracellular glycogen (8,9),
and since this effect was also detected in the positive control
animals which did not lose body weight the detected decrease
in glycogen was considered indicative of cytotoxicity.
Study 1 conclusion. As demonstrated by the DNA migration
levels in the tissues of animals exposed to cytotoxic
concentrations of a potent genotoxic carcinogen such as
EMS, the maximum dose response in DNA migration within
an experiment can easily be ,2-fold greater than the minimum
dose response depending on the sensitivity of the speciﬁc
tissues to a particular compound. But despite this limited range
and magnitude of response, the sensitivity of the comet assay
and the statistical methods used are more than adequate for
detecting small but signiﬁcant and dose-dependent increases in
DNA migration indicative of genotoxicity. While log trans-
formation of non-normally distributed data may provide
additional statistical power when the sample size is large
(e.g. population studies) and/or when inter- or intra-animal
variability is high, log transforming data when the sample size
is small (e.g. four to six animals) and/or data variability is
stable or low do not appear to enhance the overall speciﬁcity or
the sensitivity of comet analysis.
Based on the MN assay and after two daily administrations,
EMS was neither genotoxic nor cytotoxic in the bone marrow
or the peripheral blood. However, based on the comet and
LMW DNA diffusion assays in the same animals and after an
additional administration of EMS 4 h prior to sampling, EMS
was genotoxic in the peripheral blood at 25 mg/kg and in the
liver at 25 and 50 mg/kg. In the bone marrow, increased levels
of % LMW DNA diffusion that were concordant with the
increases in DNA migration detected at every dose concentra-
tion tested indicated that cytotoxicity was a confounding factor
in the determination of genotoxicity in this tissue and under the
experimental conditions of this study. In fact, despite the
absence of typical histopathological evidence of gross necrosis/
apoptosis or of changes in cell division (e.g. haematopoiesis in
the bone marrow), early evidence of dose-related cytotoxicity
(e.g. decreases in mean BW and liver glycogen combined with
increases in % LMW DNA diffusion in all the tissues sampled)
was considered sufﬁcient indication that the multiple admin-
istrations of EMS at 25, 50 and 100 mg/kg were too cytotoxic
for the accurate assessment of genotoxicity. Therefore, a repeat
comet study with lower dose concentrations and/or fewer dose
administrations was considered necessary to determine the
magnitude of EMS genotoxicity that could be detected in the
absence of cytotoxicity.
Study 2
In Study 2, the vehicle or EMS at 25, 50, 100 or 200 mg/kg
BW was orally administered to animals once 4 h prior to
sampling (Tables X–XIII). Since the 200 mg/kg dose group
received the same treatment as the standard positive control
dose group, an additional positive control group was not
included in the study. Due to the short exposure incompatible
with detecting the induction of MNs, the MN component was
not included in this study. Therefore, no animals received
administrations of CP. From each study animal, bone marrow,
peripheral blood, liver and duodenum were collected and
analysed for the comet assay.
Bone marrow. The summary of the bone marrow comet assay
analysis is presented in Table X. The bone marrow OTM, % Tail
DNA and % LMW DNA data for the concurrent vehicle control
were normally distributed (P 5 0.068, 0.139 and 0.362,
respectively). Therefore, parametric tests were used for the
statistical analysis of these parameters. After one administration
of EMS 4 h before sampling, the mean   SD Min to Max dose
response range for the OTM was 4.5   1.36 to 6.9   1.81. For
the % Tail, the Min to Max dose response range was 15.6  
2.81 to 23.3   3.82%. Based on the OTM and on the % Tail
DNA, a statistically signiﬁcant and dose-dependent (P  
0.0027) but ,2-fold increase in DNA migration was detected
Fig. 5. Histopathology of glycogen depletion in the liver. Haematoxylin- and eosin-stained normal liver from the vehicle control animals (a) compared to the liver
with depleted glycogen from animals dosed with  50 mg/kg of EMS (b).
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200 mg/kg. Based on the % LMW DNA diffusion, an increase
in cytotoxicity was not detected at any dose concentration tested.
Peripheral blood. The summary of the peripheral blood
comet assay analysis is presented in Table XI. The blood
OTM and % Tail DNA data for the concurrent vehicle control
Table X. Comet assay evaluation of bone marrow in rats exposed to one administration of EMS
Dose (mg/kg) TL (mean   SD) % Tail OTM % LMW DNA
Mean   SD P-value
a Mean   SD P-value
a Mean   SD P-value
a
Vehicle 35.9   4.85 15.6   2.81 — 4.5   1.36 — 11.0   3.74 —
25 38.2   9.42 15.8   5.32 0.4628 4.2   2.27 0.4045 10.0   4.20 0.3361
50 42.7   8.45 18.0   5.09 0.1668 4.6   2.11 0.4478 9.7   4.18 0.2867
100 49.3   4.85 22.2   3.72 þ0.0030* 6.2   1.82 þ0.0441* 11.7   2.50 0.3622
200 49.4   5.12 23.3   3.82 þ0.0013* 6.9   1.81 þ0.0127* 11.8   2.93 0.3383
One-tailed trend test P-value þ0.0003* þ0.0027* 0.1831
Data based on 100 cells scored per animal; six animals per dose group.
aOne-tailed pairwise comparison of dose group to the concurrent vehicle control.
*Statistically signiﬁcant increase (þ) or decrease ( )a tP , 0.05.
Table XI. Comet assay evaluation of peripheral blood in rats exposed to one administration of EMS
Dose (mg/kg) TL (mean   SD) % Tail OTM % LMW DNA
Mean   SD P-value
a Mean   SD P-value
a Mean   SD P-value
a
Vehicle 13.4   4.80 8.2   1.28 — 0.9   0.21 — 0.7   1.21 —
25 14.8   2.88 8.9   1.11 0.1791 0.9   0.19 0.2631 2.0   2.61 0.1970
50 19.7   3.24 10.0   0.91 þ0.0085* 1.3   0.26 þ0.0040* 5.2   2.56 þ0.0043*
100 31.3   2.32 13.9   1.32 , þ0.0001* 2.4   0.22 , þ0.0001* 8.8   3.31 þ0.0011*
200 36.9   4.97 20.0   3.63 , þ0.0001* 4.4   1.17 þ0.0003* 14.0   4.15 þ0.0010*
One-tailed trend test P-value , þ0.0001* , þ0.0001* , þ0.0001*
Data based on 100 cells scored per animal; six animals per dose group.
aOne-tailed pairwise comparison of dose group to the concurrent vehicle control.
*Statistically signiﬁcant increase (þ) or decrease ( )a tP , 0.05.
Table XII. Comet assay evaluation of liver in rats exposed to one administration of EMS
Dose (mg/kg) TL (mean   SD) % Tail OTM % LMW DNA
Mean   SD P-value
a Mean   SD P-value
a Mean   SD P-value
a
Vehicle 10.9   2.17 5.4   0.72 0.7   0.19 — 5.2   1.94 —
25 16.9   2.11 7.4   0.90 þ0.0009* 1.1   0.28 þ0.0101* 6.7   3.67 0.1985
50 24.1   3.14 9.5   0.44 , þ0.0001* 1.3   0.12 , þ0.0001* 5.5   2.74 0.4064
100 33.6   4.08 13.1   1.04 , þ0.0001* 2.5   0.43 , þ0.0001* 16.2   19.62 0.1145
200 45.4   2.24 19.7   2.26 , þ0.0001* 4.7   0.54 , þ0.0001* 13.8   5.74 þ0.0063*
One-tailed trend test P-value , þ0.0001* , þ0.0001* þ0.0221*
Data based on 100 cells scored per animal; six animals per dose group.
aOne-tailed pairwise comparison of dose group to the concurrent vehicle control.
*Statistically signiﬁcant increase (þ) or decrease ( )a tP , 0.05.
Table XIII. Comet assay evaluation of duodenum in rats exposed to one administration of EMS
Dose (mg/kg) TL (mean   SD) % Tail DNA OTM % LMW DNA
Mean   SD P-value
a Mean   SD P-value
a Mean   SD P-value
a
Vehicle 51.6   5.33 23.0   2.14 — 6.9   0.93 — 13.7   5.50 —
25 54.8   5.44 26.4   3.50 þ0.0340* 8.4   1.55 þ0.0325* 11.3   4.37 0.2174
50 54.9   4.76 26.6   4.24 þ0.0464* 8.2   2.09 0.2944 18.0   14.21 0.2510
100 56.6   6.09 29.7   5.00 þ0.0063* 9.4   2.17 þ0.0130* 16.7   15.07 0.3311
200 56.0   8.23 32.6   5.84 þ0.0042* 10.0   2.23 þ0.0043* 21.8   14.08 0.1076
One-tailed trend test P-value þ0.0002* þ0.0038* 0.0682
Data based on 100 cells scored per animal; six animals per dose group.
aOne-tailed pairwise comparison of dose group to the concurrent vehicle control.
*Statistically signiﬁcant increase (þ) or decrease ( )a tP , 0.05.
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197were normally distributed (P 5 0.971 and 0.207, respec-
tively). Therefore, parametric tests were used for the statistical
analysis of these parameters. The % LMW DNA data were
not normally distributed (P 5 0.003). Therefore, non-
parametric tests were used for the statistical analysis of this
parameter). After one administration of EMS 4 h before
sampling, the mean   SD background to maximum dose
response range was 0.9   0.21 to 4.4   1.17 for the OTM and
8.2   1.28 to 20.0   3.63 for the % Tail. Based on the OTM
and the % Tail, a statistically signiﬁcant and dose-dependent
(P , 0.0001) increase in DNA migration was detected in the
blood at 50, 100 and 200 mg/kg. Based on the % LMW DNA
diffusion, a statistically signiﬁcant and dose-dependent (P ,
0.0001) increase in cytotoxicity was also detected at 50, 100
and 200 mg/kg. Neither an increase in DNA migration nor in
cytotoxicity was detected at 25 mg/kg.
Liver. The summary of the liver comet assay analysis is
presented in Table XII. After one administration of EMS, the
mean   SD background to maximum dose response range was
0.7   0.19 to 4.7   0.54 for the OTM and 5.4   0.72 to 19.7  
2.26% for the % Tail. Based on both the OTM and the % Tail,
a statistically signiﬁcant and dose-dependent (P , 0.0001)
increase in DNA migration was detected in the liver at every
dose concentration tested with a ,2-fold increase at 25 and 50
mg/kg. Based on the % LMW DNA diffusion, a signiﬁcant
increase in cytotoxicity was only detected at the positive
control concentration of 200 mg/kg. Histopathological evalu-
ation of the liver samples found no pathology of inﬂammation,
necrosis and/or apoptosis at any dose concentration tested.
Duodenum. The summary of the duodenum analysis is
presented in Table XIII. The duodenum OTM data for the
concurrent vehicle control samples were not normally
distributed (P 5 0.021). Therefore, non-parametric tests were
used for the statistical analysis of this parameter. After one
administration of EMS 4 h before sampling, the mean   SD
background to maximum dose response range was 6.9   0.93
to 10.0   2.23 for the OTM and 23   2.14 to 32.6   5.84 for
the % Tail. Based on the OTM and the % Tail, a statistically
signiﬁcant and dose-dependent (P . 0.0038) increase in DNA
migration was detected in the duodenum at every dose
concentration tested with a ,2-fold increase at every dose.
Based on the % LMW DNA diffusion, no increase in
cytotoxicity was detected at any dose concentration tested.
Histopathological evaluation of the duodenum samples found
no pathology of inﬂammation, necrosis and/or apoptosis at any
dose concentration tested.
Study 2 conclusions. Four hours after a single oral adminis-
tration and in the absence of cytotoxicity or clinical signs of
stress, EMS was genotoxic in the bone marrow, liver and
duodenum with the LOAEL in the liver and duodenum at 25
mg/kg. In the peripheral blood, EMS was cytotoxic at doses
 50 mg/kg resulting in a statistically signiﬁcant increase in
DNA migration. However, no genotoxic or cytotoxic effects
were detected at 25 mg/kg. Based on the results from the two
independent studies, the concomitantly conducted comet and
LMW DNA diffusion assays could detect at doses as low as 25
mg/kg and after only one to three administrations the genotoxic
and cytotoxic effects of EMS that are otherwise undetectable
by the MN assay and typical histopathology evaluation. Due to
this demonstrated sensitivity of the comet assay, careful
consideration of the effects of cytotoxicity when incorporating
comet into multi-dose studies should be taken.
Discussion
Using the minimal number of animals and the standard comet
sample processing methodology published by Hartmann et al.
(1), the combined comet/MN assay protocol presented here has
proven to be a sensitive and efﬁcient method for detecting
within the same animals multiple classes of genotoxins across
a wide range of target organs. By including the LMW DNA
diffusion assay in our protocol, one can easily and effectively
detect DNA fragmentation that occurs in the earliest stages of
cell death and that can by increasing or decreasing DNA
migration confound the determination of genotoxicity using
comet. However, it is critical to be aware that the DNA
migration levels reported in this paper including those that
were ,2-fold greater than the concurrent vehicle control were
induced by both a pharmaceutical (Figure 3) as well as by
EMS, a potent genotoxic carcinogen. The exposure effects
detected by the comet and MN assays in different or even the
same tissues can vary widely depending on the tissue and the
test compound. Thus, it is ill-advised to arbitrarily assign to all
tissues and test compounds evaluated in the comet assay
speciﬁc positive response criteria (e.g. 2-fold increase) and/or
methodology (e.g. sample times or electrophoresis conditions)
based on criteria established from the MN assay and/or the
comet response of one tissue to a positive control.
All the methodologies outlined in this paper have been
proven to generate reproducible results without the incorpora-
tion of extreme technical or statistical measures to control
variability and/or sensitivity. For the successful integration of
the in vivo comet assay and as with scoring the LMW DNA
diffusion assay, experience-driven consistency and speed with
sample handling and processing are the most critical factors in
managing variability. The speciﬁcity and/or sensitivity of the
comet assay is most dependent on the appropriateness of the
study design and the interpretation of the results. For the
appropriate application and objective interpretation of the
comet assay in the safety testing of compounds and/or complex
compounds (e.g. polymer conjugates) with ambiguous or
unknown genotoxicity, we recommend the following:
  To ensure that the optimal doses and/or sample times are
used, the pharmacokinetics (e.g. Cmax) and the cytotoxicity
of a test compound should be determined prior to or
concurrently with the combined comet/MN assay and based
on the comet/MN dosing regime.
  To measure cytotoxicity and/or to determine the MTD
relevant to the comet assay, early or sensitive detection
methods such as LMW DNA diffusion, plasma enzyme
levels and/or histopathological evidence of glycogen de-
pletion should be used.
  Since cytotoxicity can confound the ability to determine
genotoxicity in comet, include in the dose range tested at least
two to three doses that are non-cytotoxic in the sampled tissues
to allow for the determination of a dose response.
  In cases where dose-limiting cytotoxicity in one tissue
conﬂicts with the target tissue of interest, the minimum dose
at which cytotoxicity occurs in any tissue may be considered
the MTD and toxicokinetic/autoradiographic data may be
used to provide evidence of target tissue exposure.
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data interpretation account for and make necessary adjust-
ments for the different tissues and the different forms of
genotoxins that can express DNA damage as increases or
decreases (e.g. cross-linkers) in DNA migration.
  Describe in the results/conclusions any confounding factors
(e.g. cytotoxicity and cell division) that may have inﬂuenced
DNA migration.
  Account for the possibility that a non-linear or non-
monotonic dose–response relationship may exist.
  Present and address data from every dose group for unbiased
review and interpretation of the dose response.
  Only use historical control comet data to demonstrate
proﬁciency with comet in speciﬁc tissues and as justiﬁcation
for the methodology (e.g. electrophoresis conditions) used
for a particular tissue type.
  Limit comparisons of exposure dose groups to concurrent
controls and determine the response relative to the range
between the concurrently detected minimum (e.g. vehicle
control) and maximum response (e.g. positive control) under
the experimental conditions of the study.
  Standard statistical analysis methods with pre-determined
criteria (e.g. 95% conﬁdence levels) and the appropriate
adjustments for data distribution and variability should be
used to determine the statistical signiﬁcance of a response.
  Classify genotoxicity and/or biological relevance on the
reproducibility of a signiﬁcant response rather than the
absolute magnitude (e.g. x-fold) of the response.
The recommendations presented here provide an effective
methodology for combining the in vivo comet and MN assays
and for interpreting comet assay data. This approach provides
to safety testing critical target organ data increasing sensitivity
while minimizing animal usage, exposure times and toxicity.
Supplementary data
Supplementary ﬁgures are available at Mutagenesis Online.
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